Search

Your search keyword '"Chouaïd C"' showing total 107 results

Search Constraints

Start Over You searched for: Author "Chouaïd C" Remove constraint Author: "Chouaïd C" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
107 results on '"Chouaïd C"'

Search Results

3. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

6. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

9. Explore ALK : Alectinib chez les patients atteints de cancer du poumon non à petites cellules métastatique ALK+: une analyse nationale en vie réelle (GFPC 03-2019)

12. 76P Immune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line or later (2L+) nivolumab (nivo): A French I-O optimise analysis

15. 58O Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study

21. Efficacité du Pembrolizumab en première ligne de prise en charge de cancers du poumon non à petites cellules métastatiques, PDL1 ≥ 50 % avec métastases cérébrales (étude ESCKEYP – GFPC 05–2018)

25. LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6

32. Résultats intermédiaires sur les 658 premiers patients de l’étude PRAISE (Patient-Reported AutoImmunity SEcondary to cancer immunotherapy) : étude de cohorte prospective multicentrique pour le suivi des manifestations auto-immunes sous immunothérapie

34. CO73 Amivantamab Versus Real-World Clinical Practice in Europe and the US for Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

42. 1016P GFPC 06-2018: A multicentre phase II, open-label, non-randomized study evaluating platinum-pemetrexed-atezolizumab (+/- bevacizumab) for patients with stage IIIB/IV non-squamous NSCLC with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies

47. BRIGAROS : évaluation du brigatinib en accès compassionnel chez les patients porteurs d’un cancer bronchique non à petites cellules avec réarrangement de ROS1

Catalog

Books, media, physical & digital resources